✦ LIBER ✦

Response of low-grade oligodendroglial tumors to temozolomide

✍ Scribed by Thomas N. Byrne

Publisher: Springer US
Year: 2004
Tongue: English
Weight: 53 KB
Volume: 70
Category: Article
ISSN: 0167-594X
DOI: 10.1007/s11060-004-5896-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

MGMT methylation: A marker of response t

MGMT methylation: A marker of response to temozolomide in low-grade gliomas

✍ Sibille Everhard; Gentian Kaloshi; Emmanuelle Crinière; Alexandra Benouaich-Amie 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 1 views

Early metabolic responses in temozolomid

Early metabolic responses in temozolomide treated low-grade glioma patients

✍ Matthias Wyss; Silvia Hofer; Matthias Bruehlmeier; Martin Hefti; Catrina Uhlmann 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 278 KB

Successful treatment of low-grade oligod

Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine

✍ Elize M. Biemond-ter Stege; Johan M. Kros; Hein G. de Bruin; R. H. Enting; Irene 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 297 KB

Durable response of a radiation-induced,

Durable response of a radiation-induced, high-grade cerebellar glioma to temozolomide

✍ Michelle L. Monje; Naren R. Ramakrishna; Geoffrey Young; Jan Drappatz; Lisa M. D 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 314 KB

MGMT immunoexpression predicts responsiv

MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy

✍ Kalman Kovacs; Bernd W. Scheithauer; Matilde Lombardero; Roger E. McLendon; Luis 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 221 KB

Response to low dose temozolomide in rad

Response to low dose temozolomide in radiation induced gliomatosis cerebri

✍ Hargrave, D. ;Bouffet, E. ;Gammon, J. ;Becker, L. ;Rutka, J. ;Baruchel, S. 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB

{ Sylvain Baruchel is the Principal Investigator of an industry sponsored study (Schering-Plough). He receives no monetary compensation. Grant sponsor: Temodal 1 (the manufacturers of temozolomide), Schering Plough, Inc. (for the Phase I Clinical Trial).